These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 25877834)

  • 1. Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement.
    Albanese A; Abbruzzese G; Dressler D; Duzynski W; Khatkova S; Marti MJ; Mir P; Montecucco C; Moro E; Pinter M; Relja M; Roze E; Skogseid IM; Timerbaeva S; Tzoulis C
    J Neurol; 2015 Oct; 262(10):2201-13. PubMed ID: 25877834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. British Neurotoxin Network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin.
    Marion MH; Humberstone M; Grunewald R; Wimalaratna S
    Pract Neurol; 2016 Aug; 16(4):288-95. PubMed ID: 26976927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current use of neurotoxins for alleviating symptoms of cervical dystonia.
    Aradi S; Hauser RA
    Expert Rev Neurother; 2024 Aug; 24(8):787-797. PubMed ID: 39049547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B.
    Oshima M; Deitiker PR; Jankovic J; Duane DD; Aoki KR; Atassi MZ
    J Neuroimmunol; 2011 Dec; 240-241():121-8. PubMed ID: 22079193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pain Relief in Cervical Dystonia with Botulinum Toxin Treatment.
    Camargo CH; Cattai L; Teive HA
    Toxins (Basel); 2015 Jun; 7(6):2321-35. PubMed ID: 26110508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin therapy for cervical dystonia.
    Jankovic J
    Neurotox Res; 2006 Apr; 9(2-3):145-8. PubMed ID: 16785112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum Toxin Therapy for Parkinson's Disease.
    Wagle Shukla A; Malaty IA
    Semin Neurol; 2017 Apr; 37(2):193-204. PubMed ID: 28511260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin treatment of axial and cervical dystonia.
    Benecke R; Dressler D
    Disabil Rehabil; 2007 Dec; 29(23):1769-77. PubMed ID: 18033602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials.
    Chinnapongse RB; Lew MF; Ferreira JJ; Gullo KL; Nemeth PR; Zhang Y
    Clin Neuropharmacol; 2012; 35(5):215-23. PubMed ID: 22932474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
    Pappert EJ; Germanson T;
    Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia.
    Swope D; Barbano R
    Neurol Clin; 2008 May; 26 Suppl 1():54-65. PubMed ID: 18603168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life in long-term botulinum toxin treatment of cervical dystonia: Results of a cross sectional study.
    Moll M; Rosenthal D; Hefter H
    Parkinsonism Relat Disord; 2018 Dec; 57():63-67. PubMed ID: 30150129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy?
    Jinnah HA; Comella CL; Perlmutter J; Lungu C; Hallett M;
    Toxicon; 2018 Jun; 147():89-95. PubMed ID: 28888929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review.
    Colosimo C; Tiple D; Berardelli A
    Neurotox Res; 2012 Nov; 22(4):265-73. PubMed ID: 22359151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of cervical dystonia with botulinum toxins.
    Comella CL; Thompson PD
    Eur J Neurol; 2006 Feb; 13 Suppl 1():16-20. PubMed ID: 16417593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The barriers and facilitators to satisfaction with botulinum neurotoxin treatment in people with cervical dystonia: a systematic review.
    Boyce MJ; McCambridge AB; Bradnam LV; Canning CG; Verhagen AP
    Neurol Sci; 2022 Aug; 43(8):4663-4670. PubMed ID: 35593979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F.
    Eleopra R; Tugnoli V; Quatrale R; Rossetto O; Montecucco C; Dressler D
    Neurotox Res; 2006 Apr; 9(2-3):127-31. PubMed ID: 16785109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration of botulinum toxin efficacy in cervical dystonia clinical trials: A scoping review.
    Castagna A; Jinnah HA; Albanese A
    Parkinsonism Relat Disord; 2024 Aug; 125():107011. PubMed ID: 38909588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: a critical reappraisal.
    Marsili L; Bologna M; Jankovic J; Colosimo C
    Expert Opin Drug Saf; 2021 Jun; 20(6):695-705. PubMed ID: 33831328
    [No Abstract]   [Full Text] [Related]  

  • 20. Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes.
    Jinnah HA; Goodmann E; Rosen AR; Evatt M; Freeman A; Factor S
    J Neurol; 2016 Jun; 263(6):1188-94. PubMed ID: 27113604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.